Corticotherapy during pregnancy demonstrates a relative success in reducing mortality and distress respiratory syndrome incidence in the pre-term newborn. In spite of these immediate benefits, it has been described that babies born to betamethasone-treated mothers develop increased cardiovascular risk at the adolescence. Attempting to evaluate whether this cardiovascular risk can be associated to an unfavorable lipid profile in the mothers we have developed a pilot study to assess the long-term changes of lipid metabolism in mothers treated with betamethasone during pregnancy (CAAE: 45790715.7.0000.5404). The control groups group (n=31) was consisted by women who did not use betamethasone and underwent uncomplicated gestation and delivery. Mothers that received betamethasone (n=15) presented a trend towards increased LDL and reduced HDL levels. The alpha limit of 0.05 was not reached by the comparisons but the power (1-beta) remained around 20%. Aims: To assure whether exists a difference in LDL and HDL later in life in women who received betamethasone during pregnancy (Case) as compared to women that did not receive betamethasone during pregnancy (Control). Subjects and methods: We will prospect deliveries that occurred in CAISM 19 to 22 months before samples collection. The exclusion and inclusion criteria will be the same for the pilot study (CAAE: 45790715.7.0000.5404).The voluntaries will be invited by phone call and asked to come for a single visit after consenting to participate (TCLE signature). 102 case and 86 controls will be invited. Total cholesterol, TG and HDL will be assessed and LDL levels will be calculated. Data analysis: Comparisons of the means from Cases and Controls will be performed by student t-test or Mann-Whitney depending on the parametric distribution (Shapiro). Total cholesterol, LDL, TG and HDL will be analyzed. The alpha limit for difference will be of 0.05.
News published in Agência FAPESP Newsletter about the scholarship: